2025 Insurance Coverage and Processing Packaging 
PharmaTech
JUNE 10, 2025
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. On June 9, 2025, Secretary of Health and Human Services Robert F. Kennedy Jr.
Pharmaceutical Technology
JUNE 6, 2025
Robert Barrie June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US health secretary Robert F Kennedy Jr. The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. Topic sponsors are not involved in the creation of editorial content.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 30, 2025
Robert Barrie June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook CAR-Ts, the first of which were initially approved in June 2025, have demonstrated a wealth of efficacy in haematological oncology indications. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Express Pharma
MARCH 16, 2025
On the global stage, AI and Machine Learning (ML) drove drug discovery and process optimisation, especially as large-scale pharma companies adopted AI for precision medicine. Building sophisticated laboratories, recruiting scientific talent, and collaborating with global research institutions are essential steps in this process.
Pharmaceutical Technology
JUNE 23, 2025
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Technology
JUNE 12, 2025
June 12, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Stargardt disease is a genetic retinal condition, resulting in progressive loss of vision and blindness. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Give your business an edge with our leading industry insights.
Putting Patients First Blog
MARCH 18, 2024
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
Expert insights. Personalized for you.
85 
Let's personalize your content